Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant

Roswell Park Comprehensive Cancer Center has earned its most highly rated grant from the National Cancer Institute (NCI). The NCI renewed Roswell Park’s status as a Comprehensive Cancer Center – a designation held by less than 4% of cancer centers- awarding Roswell Park the highest possible “Exceptional” rating as it renewed a grant Roswell Park has successfully competed for since 1972.

Clinical trials show promise in treating central nervous system lymphoma, breast cancer, and glioblastoma

Dana-Farber Cancer Institute researchers are leading 3 separate studies with encouraging results in treating patients with central nervous system (CNS) lymphoma, breast cancer, and glioblastoma. These findings are among more than 80 studies presented at ASCO that are led by Dana-Farber-affiliated researchers.

ASCO: Large precision oncology study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of U.S. veterans

A new study(Link is external) (Link opens in new window) led by a UCLA-VA collaborative team looking at the landscape of genomic alterations in more than 5,000 veterans with metastatic prostate cancer uncovered differences in the genomic makeup of cancer cells that were associated with race and ethnicity.

Dr. Daniel Geynisman Named New Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network

Daniel M. Geynisman, MD, is being announced the new Editor-in-Chief for JNCCN—Journal of the National Comprehensive Cancer Network. Dr. Geynisman, Chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, has a long history of working with NCCN in a variety of roles.

CHOP, Stanford Researchers Identify Protein That Controls CAR T Cell Longevity

CAR T cell therapy has revolutionized the way certain types of cancer are treated, and the longer those CAR T cells live in a patient’s body, the more effectively they respond to cancer. Now, researchers have found that a protein called FOXO1 improves the survival and function of CAR T cells, which may lead to more effective CAR T cell therapies and could potentially expand its use in difficult-to-treat cancers.

AACR: PARP1-selective inhibitor demonstrates early efficacy in breast cancers with DNA repair defects

The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.

Penn Medicine at the AACR Annual Meeting 2024

Researchers from the Abramson Cancer Center (ACC) and Perelman School of Medicine at the University of Pennsylvania will present data on the latest advances in cancer science and medicine at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Researcher’s microscale tech is chipping away at cancer, organ failure and neurological disease

For outstanding contributions to engineering of biomimetic tissue-on-chip technologies and organoids for disease modeling and regenerative medicine, ASU’s Mehdi Nikkhah has been inducted as a Fellow into the American Institute for Medical and Biomedical Engineering.

Cancer Research in 3D

In cancer research, seeing is believing. Before they can diagnose or treat cancer, researchers and doctors need to have a clear understanding of what’s happening at a microscopic level. While existing technology allows us to see things the naked eye can’t, a team of researchers at the Department of Energy’s Oak Ridge National Laboratory (ORNL) is working to standardize a process for staining and seeing cancer in a whole new perspective – in 3D (three dimensions).

LJI welcomes new faculty member Miguel Reina-Campos, Ph.D.

Cancer researcher Miguel Reina-Campos, Ph.D., has joined the faculty of La Jolla Institute for Immunology (LJI) as an Assistant Professor to lead the Laboratory of Tissue Immune Networks. His laboratory at LJI aims to investigate the basis of CD8+ T cell tissue immunity to improve life-saving cancer immunotherapies.

Researchers uncover a potential genetic marker associated with better survival outcomes in patients with head and neck cancer

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center show for the first time that a gene usually linked to giant axonal neuropathy, a rare and severe neurological condition, also plays a role in inhibiting aggressive tumor cell growth in head and neck cancers.

New treatment for a rare and aggressive cancer improves survival rates in breakthrough clinical trial

An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.

Clues to early onset colorectal cancer found in microbiome of Hispanic patients

Nina Sanford, M.D., Chief of Gastrointestinal Radiation Oncology Service, UT Southwestern Medical Center Most people have a screening colonoscropy around age 50, however recent research has uncovered a rise in early onset colorectal cancer in patients younger than 50. What can…

Immunotherapy before surgery leads to promising long-term survival in sarcoma patients

Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center

Case Western Reserve University researcher awarded $2 million federal grant to further explore possible new effective treatments for colorectal and other cancers

With a new $2 million federal grant, a researcher with the Case Western Reserve University School of Medicine will lead a team to further explore preliminary findings of an effective treatment for colorectal and possibly other cancers.

Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation

The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the United States.

Cancer Prevention and Research Institute of Texas Awards $7.5 Million to Baylor Scott & White Research Institute

Baylor Scott & White Research Institute will establish the Texas site of the Connect for Cancer Prevention StudyTM (Connect), a project of the National Cancer Institute (NCI), part of the National Institutes of Health. Nine healthcare systems plan to enroll 200,000 adults across the U.S.

Antibody-drug conjugate helps patients with metastatic non-small cell lung cancer live longer, delaying disease progression

Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small cell lung cancer, an improvement that was primarily driven by patients with non-squamous tumors.

Using recent diagnostic scans can substantially cut time to treatment for patients needing urgent palliation

Using previously taken diagnostic computed tomography (CT) scans in place of CT simulation scans to plan simple palliative radiation treatments can substantially reduce the time some people spend waiting for urgent treatment, improving the patient experience, a new study suggests.

Precision medicine navigators increase genomic testing rates for Black patients with prostate cancer

The presence of a clinical navigator to act as a liaison between people with prostate cancer and the health care system greatly increases the likelihood that patients, especially Black patients, will receive advanced testing that can help predict the severity of their disease and guide treatment, a new study suggests.

Short-course radiation as effective as standard treatment for patients who opt for breast reconstruction after mastectomy

In a first-of-its-kind study, people with breast cancer who underwent implant-based breast reconstruction immediately following a mastectomy reported that getting fewer, higher doses of radiation was just as effective as standard radiation, did not increase side effects and saved them time and money.

High cure rate, low toxicity maintained with shortened radiation treatment for intermediate risk prostate cancer, study finds

People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggests.